Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $19.6 million.

  • Ligand Pharmaceuticals' Shares Outstanding (Weighted Average) rose 629.24% to $19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.6 million, marking a year-over-year increase of 629.24%. This contributed to the annual value of $18.3 million for FY2024, which is 573.48% up from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Shares Outstanding (Weighted Average) stood at $19.6 million for Q3 2025, which was up 629.24% from $19.3 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $19.6 million during Q3 2025, with a 5-year trough of $16.4 million in Q1 2021.
  • Over the past 5 years, Ligand Pharmaceuticals' median Shares Outstanding (Weighted Average) value was $17.3 million (recorded in 2023), while the average stood at $17.5 million.
  • In the last 5 years, Ligand Pharmaceuticals' Shares Outstanding (Weighted Average) crashed by 56.87% in 2021 and then soared by 822.81% in 2025.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $16.6 million in 2021, then rose by 1.43% to $16.9 million in 2022, then rose by 2.55% to $17.3 million in 2023, then rose by 5.73% to $18.3 million in 2024, then rose by 7.04% to $19.6 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $19.6 million in Q3 2025, compared to $19.3 million in Q2 2025 and $19.2 million in Q1 2025.